Hein-Rothweiler R, Mudra H
Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin, Städtisches Klinikum München GmbH, Klinikum Neuperlach, Oskar-Maria-Graf-Ring 51, 81737, München, Deutschland.
Herz. 2013 Nov;38(7):714-9. doi: 10.1007/s00059-013-3964-2.
Scientific data underlying current guidelines on treatment of carotid artery stenosis is subject to interdisciplinary discussion. In particular selective weighting of the randomized European studies leads to conflicting levels of recommendation and levels of evidence, especially when directly comparing guidelines under surgical versus endovascular guidance. Surgical guidelines recommend a limitation of carotid artery stenting (CAS) to symptomatic patients with specific surgical/anatomical disadvantages and/or severe comorbidities. The European Society of Cardiology (ESC) guidelines recommend the use of CAS only in patients at increased surgical risk but at the same time requires morbidity and mortality rates comparable to those of surgical interventions. Even one step further, the American guidelines and specifically the associated comments of the German Society of Cardiology on the above mentioned ESC guidelines put CAS and carotid endarterectomy (CEA) on a par in terms of treatment alternatives, presupposing analogous CEA complication rates. Differential interpretation of the so far inadequate data is a common issue of current evidence-based medicine. The difficulty in conceptualization of new studies concerning the therapy of carotid stenosis lies in the funding these large projects and also on the high patient number required to achieve adequate statistical power. Furthermore, during the estimated long study period substantial changes of current techniques and devices can be anticipated which might render the study results in part outdated by the time of publication. However, as long as no new randomized study results comparing medical, surgical and interventional treatment of carotid stenosis are available, the question on the optimal therapy for patients with carotid artery disease remains unanswered.
当前颈动脉狭窄治疗指南所依据的科学数据有待跨学科讨论。尤其是对欧洲随机研究的选择性加权导致了推荐级别和证据级别相互矛盾,特别是在直接比较手术指导与血管内介入指导下的指南时。手术指南建议将颈动脉支架置入术(CAS)限制用于具有特定手术/解剖学劣势和/或严重合并症的有症状患者。欧洲心脏病学会(ESC)指南建议仅在手术风险增加的患者中使用CAS,但同时要求其发病率和死亡率与手术干预相当。更进一步,美国指南,特别是德国心脏病学会对上述ESC指南的相关评论,在假定颈动脉内膜切除术(CEA)并发症发生率相似的情况下,将CAS和CEA作为同等的治疗选择。对目前尚不充分的数据进行不同解读是当前循证医学的一个常见问题。关于颈动脉狭窄治疗的新研究在概念化方面的困难在于为这些大型项目提供资金,以及需要大量患者以获得足够的统计效力。此外,在预计的漫长研究期间,当前技术和设备可能会发生重大变化,这可能会使研究结果在发表时部分过时。然而,只要没有新的比较颈动脉狭窄药物、手术和介入治疗的随机研究结果,颈动脉疾病患者的最佳治疗方案问题仍未得到解答。